 Home > Medical News > Latest Medical News > Fuhong Hanlius' ``bevacizumab'' biosimilar drug approved in China

Fuhong Hanlius' ``bevacizumab'' biosimilar drug approved in China

 Last Update: 2022-01-12
 Source: Internet
 Author: User

Tags

cell time cellular

small data

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

ArticleMedicine Guanlan

On December 2, China's National Food and Drug Administration (NMPA) announced that the listing application of the bevacizumab biosimilar HLX04 declared by Fuhong Henlius had been approved

Bevacizumab is a humanized monoclonal antibody IgG1, which is a vascular endothelial growth factor (VEGF) inhibitor

Public information shows that HLX04 is a bevacizumab biosimilar developed by Henlius in accordance with the Technical Guidelines for the Development and Evaluation of Biosimilars (Trial).

According to a press release issued by Fuhong Henlius earlier, HLX04 selected the indication for metastatic colorectal cancer in the design of the phase 3 clinical study

This is a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical trial named HLX04-mCRC03.

It is worth mentioning that the Phase 1 clinical study results of the similarity between HLX04 and the original product, and the Phase 3 clinical study results of combined chemotherapy for the treatment of patients with metastatic colorectal cancer have been published in the internationally renowned journal Cancer Chemotherapy and Pharmacology ( CCP) and BioDrugs

references:

[1] On December 2, 2021, the drug approval document pending information is released.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.